Table 4.
Annual costs spent and averted per disease state in 2035
| In billions 2015 US$, discounted by 3.0% annually | |||||
| State | No intervention (CI) | 20% reduction (CI) | Difference (CI) | 50% reduction (CI) | Difference (CI) |
| Steatosis | 6.48 (6.43–6.53) | 6.40 (6.35–6.45) | 0.08 (0.080–0.082) | 6.23 (6.18–6.28) | 0.25 (0.248–0.255) |
| NASH | 5.26 (5.22–5.30) | 4.89 (4.85–4.93) | 0.37 (0.368–0.375) | 4.11 (4.08–4.14) | 1.15 (1.139–1.162) |
| Cirrhosis | 7.00 (6.93–7.07) | 6.22 (6.16–6.28) | 0.78 (0.772–0.791) | 4.60 (4.56–4.65) | 2.40 (2.371–2.429) |
| HCC | 5.10 (5.04–5.16) | 4.55 (4.50–4.60) | 0.55 (0.537–0.558) | 3.40 (3.36–3.44) | 1.70 (1.669–1.721) |
| CHD | 162.2 (160.9–163.6) | 160.1 (158.8–161.5) | 2.09 (2.06–2.12) | 155.7 (154.4–157.0) | 6.51 (6.43–6.58) |
| T2D | 200.0 (198.4–201.6) | 195.9 (194.3–197.5) | 4.07 (4.02–4.12) | 187.4 (185.9–188.9) | 12.59 (12.46–12.73) |
| Overweight | 16.4 (16.3–16.5) | 16.6 (16.5–16.8) | -0.25 (-0.26− -0.25) | 17.2 (17.1–17.3) | -0.79 (-0.81− -0.78) |
| Obesity | 52.7 (52.3–53.1) | 50.1 (49.7–50.5) | 2.59 (2.57–2.62) | 44.7 (44.3–45.0) | 8.03 (7.95–8.12) |
| Total | 455.1 (451.4–458.9) | 444.9 (441.2–448.5) | 10.3 (10.2–10.4) | 423.3 (419.8–426.8) | 31.8 (31.5–32.2) |
CHD, coronary heart disease; CI, 95% central coverage interval; HCC, hepatocellular carcinoma; NASH, non-alcoholic steatohepatitis; T2D, type 2 diabetes.
Numbers might not add up due to rounding.